Bavarian Nordic goes 2 for 2 in pivotal chikungunya vaccine trials, teeing up filing to rival Valneva

Bavarian Nordic’s chikungunya virus vaccine candidate has racked up a second phase 3 victory. Weeks after presenting positive data in seniors, the biotech has revealed pivotal results in younger adults that position it to file for approval next year to challenge Valneva for the emerging opportunity.